Transcript Nick Thatcher - Chair`s Opening

Challenges for the treatment of
pancreatic and renal cell cancer
Nick Thatcher
Christie Hospital NHS Trust
Manchester, UK
Thursday 7 February 2008
Agenda
17.00
Chair’s opening
Nick Thatcher
17.05
Charting a new landscape in advanced pancreatic cancer
Malcolm Moore
17.35
Anti-VEGF therapy: a revolution in care for patients with
renal cell cancer
Frank Griesinger
18.05
Discussion and close
19.00
Evening dinner at the Shangri-la Hotel
Pancreatic cancer: high medical need
 Particularly difficult-to-treat disease
– late diagnoses and high mortality rates
 Gemcitabine in combination with erlotinib is a new
standard of care in metastatic disease
 Fluoropyrimidines also used
 Many regimens or new agents have failed to show
significant survival advantage over gemcitabine
alone1–4
1Louvet
2Stathopoulos,
C, et al. J Clin Oncol 2005;23:3509–16
et al. J Clin Oncol 2005;23(Suppl 16):334s (Abstract 4106)
3Xie de R, et al. Chin J Dig Dis 2006;7:49–54
4El-Rayes BF, et al. Clin Adv Hematol Oncol 2003;1:430–4
Pancreatic cancer: what are the
challenges that we face in the next decade?
 Improved understanding of disease biology
 Facilitating the identification of patients with
pancreatic cancer: the challenges and practicalities
of earlier diagnosis
 Identifying novel therapies or therapeutic
combinations to improve patient outcomes in
advanced pancreatic cancer
 Investigating potential biomarkers to predict
outcomes with specific therapeutic agents
Targeting RCC: expanding
options in the past decade
1998
2008
Interferon alfa
Bevacizumab
Interleukin-2
Sorafenib
Sunitinib
Temsirolimus
RCC = renal cell cancer
RCC: what are the challenges
that we face in the next decade?
 Optimising outcomes in RCC through best use of
available agents in combination or sequence
 Redefining the role of immunotherapy in the era of
novel agents
 Establishing the optimal dose and regimen of novel
agents in RCC and whether dose escalation improves
outcomes
 Examining how the nature of the targets for novel
therapies in RCC influences side-effect profiles
 Determining the role of novel agents in specific
patient groups (e.g. those with brain metastases,
patients with non-clear-cell tumours)
 Identification of validated biomarkers